fda bpc 157 category 2 compounding 2023 1 vs. Category 2. The FDA's peptide update, explained. Category peptides are on the FDA's “difficult to compound” list, which effectively blocks licensed pharmacies from producing them. Category 1 means You may have heard buzz
You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled Repost @peptides with @use.repost BREAKING NEWS! Today's 86 advisory vote for BPC 157 is one of the biggest peptide regulatory developments we've seen in years. While nothing changes immediately, the recommendation represents BPC 157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank
Pay in 4 interest-free payments of $5.74 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10